Full Press Release Details
ImmunoTech Inc. Announces a Second DoD Award, This One of $8.3 Million, to Fund Phase 2 Clinical Trial to Study Ampligen as Part
of a New Treatment for Brain-Metastatic Breast Cancer at the Moffitt Cancer Center
Ampligen-Related Strategy for Treating Advanced Breast Cancer Helps Earn Breakthrough Award'
Fla., September 24, 2019 - AIM ImmunoTech (NYSE American: AIM), an immuno-pharma company focused on the research and development
of therapeutics to treat multiple types of cancers, today announces the U.S. Department of Defense (DoD) has granted $8.32 million
in funding in another "Breakthrough Award". This award is to Moffitt Cancer Center for a Phase 2 clinical study of
a combination of therapies, including the Company's drug Ampligen, in patients with brain-metastatic breast cancer (BMBC).
grant to Moffitt Cancer Center was made possible by the unique complementary preclinical and clinical expertise of the teams of
Dr. Brian Czerniecki of Moffitt Cancer Center and Dr. Pawel Kalinski of Roswell Park. The researchers hypothesize that vaccination
with HER2/HER3-loaded dendritic cells (alpha-DC1s) combined with tumor-selective chemokine modulation (CKM) will be clinically
effective and may enhance antitumor efficacy of PD-1 blockade when treating BMBC. Ampligen is a component of CKM therapy.
ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of
cancers. AIM's flagship products include the Argentina-approved drug rintatolimod (trade names Ampligen
or Rintamod ) and the FDA-approved drug Alferon N Injection . Based on results of published, peer-reviewed
pre-clinical studies and clinical trials, AIM believes that Ampligen may have broad-spectrum anti-viral and anti-cancer
properties. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant
melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. These and other potential
uses will require additional clinical trials to confirm the safety and effectiveness data necessary to support regulatory approval
and additional funding. Rintatolimod is a double-stranded RNA being developed for globally important debilitating diseases and
disorders of the immune system.
of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties.
For example, no assurance can be given as to whether the current or planned trials will be successful or yield favorable data
and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities
at the institutions sponsoring other trials. In addition, initiation of planned clinical trials may not occur secondary to many
factors including lack of regulatory approval(s) or lack of study drug. Even if these clinical trials are initiated, we cannot
assure that the clinical studies will be successful or yield any useful data. Among other things, for forward-looking statements,
we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform
Act of 1995. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We
do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date
hereof. This press release and prior releases are available at www.aimimmuno.com. The information found on our website is not
incorporated by reference into this press release and is included for reference purposes only.